Pneumagen Announces Scientific Advisory Board and Development Team Appointments

 Leading Virology Experts Support Development of Neumifil for Viral Infections, Including COVID-19

16 Sept 2020 – St Andrews, Scotland – Pneumagen Ltd, focused on treating infectious diseases by targeting the human glycome, today announced completion of its new Scientific Advisory Board, with the addition of Dr Richard J. Webby at the St. Jude Children’s Research Hospital, USA, and Professor Jürgen Haas at the Edinburgh Medical School, UK.

The company also announces that Dr David Howat has been appointed as Development Director. Dr. Howat has run drug development in many small biotech/pharmaceutical companies, most recently at Haoma Medica Ltd and previously at Evgen Plc. During these projects he managed CMC, safety toxicology, regulatory, and clinical trial activities.

Read full release